The biosimilar marketing challenge of building confidence in a new category

Key takeaways

• Biosimilars have FDA approval, strong data and lower prices, yet adoption lags: roughly 76 had been approved in the U.S. by late 2025 while market penetration stayed under 20%, according to legal analyses of FDA’s reform announcement.
• The marketing job is changing minds, not building awareness, because the reference biologic already has prescriber loyalty and patient trust.
• Rules are shifting: FDA’s October 2025 draft guidance says comparative efficacy studies often aren’t needed and that switching studies are generally not recommended for interchangeability.
• Prescribers need immunogenicity data, clear explanations of extrapolation and real-world evidence; payers need plan-level economics; patients need plain-language reassurance and support.
• The strongest campaigns coordinate all three audiences with consistent messages, segmented content and ongoing real-world evidence.

Biosimilars come with FDA approval, solid evidence and lower costs, but adoption still trails expectations. Prescribers hesitate, patients worry about switching and payers push for uptake while many physicians stay cautious. The central marketing task is building confidence in a category as well as a product. This guide explains how biosimilar marketers can earn that confidence with prescribers, payers and patients.

Why does biosimilar marketing require a different approach than traditional drug marketing?

Biosimilar marketing requires a different approach because the reference biologic already holds physician loyalty and patient familiarity, so the goal is shifting established beliefs rather than introducing something new. Marketers have to show clinical equivalence without implying that past prescribing choices were wrong.

The generic drug comparison only goes so far. Generics are chemically identical to their reference drugs. Biosimilars are highly similar to their reference biologics, with no clinically meaningful differences, because biologics are large, complex molecules made in living cells. FDA’s 351(k) pathway accounts for that complexity.

The regulatory picture is moving in biosimilars’ favor. On October 29, 2025, FDA issued draft guidance proposing that many comparative efficacy studies are unnecessary when analytical testing shows biosimilarity, and said it generally no longer recommends switching studies to support interchangeability. The same analysis noted about 76 biosimilars approved since 2015, with U.S. market penetration still under 20%.

Still, “highly similar” leaves room for doubt, and that doubt is where marketing does its hardest work. At Emulent, we see many biosimilar brands launch with strong data and weak storytelling. Approval is earned through regulators; confidence is earned through consistent communication that starts before launch.

Which three audiences decide biosimilar adoption?

Prescribers, payers and patients decide biosimilar adoption, and each weighs different concerns. Focusing on only one or two slows uptake even for a strong product.

How each audience views biosimilars:

• Prescribers. Their first concern is patient safety and matching the reference product’s outcomes. They want peer-reviewed evidence, real-world data and confidence that switching stable patients is low risk.
• Payers and pharmacy benefit managers. They focus on cost, formulary control and appropriate use, and need clinical proof to justify preferring a biosimilar.
• Patients. People with autoimmune conditions, cancer or other chronic illnesses value stability and trust their current therapy. They need reassurance that a switch won’t put their health at risk.

What do prescribers need before they recommend a biosimilar?

Prescribers need immunogenicity data, a clear scientific explanation of indication extrapolation, an understanding of interchangeability, real-world evidence, peer perspectives and hands-on switching support. Many are comfortable starting new patients on biosimilars; hesitation centers on switching patients who are stable.

Seven areas that most affect prescriber confidence:

Physician education works best when it builds clinical judgment rather than listing product features. Prescribers want to understand the science well enough to own the recommendation.

How do payer relationships and formulary placement drive market access?

Payer relationships and formulary placement drive access because coverage decisions determine whether a biosimilar is affordable to patients and workable for prescribers. Payers and PBMs balance clinical evidence, savings and administrative risk, so price alone limits the conversation.

Formulary decisions involve medical directors, pharmacy and therapeutics committees and plan sponsors. The clinical story counts alongside the rebate structure.

Five considerations for reaching payers:

• Plan-level economics. Show total savings across covered lives, including downstream costs such as monitoring.
• Coverage rules. Step therapy and prior authorization can slow uptake; show how formulary design affects outcomes and total cost of care.
• Specialty pharmacy relationships. Many biologics and biosimilars are dispensed through specialty pharmacies, which influence what patients receive.
• Preferred tier placement. A preferred position gives patients and prescribers a financial reason to choose the biosimilar.
• Rebate dynamics. Reference product rebates can make biosimilars less attractive to some PBMs, so understand each payer’s incentives.

How do you build patient confidence when a switch feels uncertain?

Build patient confidence by leading with plain-language reassurance about safety, supporting patients during the switch and partnering with advocacy organizations, then adding cost benefits as a second message. Many teams underinvest here, though patient acceptance often decides whether formulary placement and physician recommendations turn into actual use.

People with serious illness need to trust safety before they think about cost.

Five elements of patient confidence-building:

• Plain-language education. Explain what “highly similar” and “no clinically meaningful differences” mean for daily treatment.
• Translation of regulatory terms. Regulatory language alone isn’t reassuring; connect it to what patients will experience.
• Transition support. Nurse lines, support coordinators and access to medical information during a switch reduce anxiety.
• Advocacy partnerships. Organizations focused on rheumatoid arthritis, inflammatory bowel disease or cancer already have patient trust and can distribute balanced education.
• Cost and access as a second layer. Once patients feel clinically confident, savings become a meaningful added reason.

Patients don’t need to understand biosimilar development. They need to know the treatment is safe, their doctor supports the change and someone is available if questions come up. Our healthcare marketing team builds patient education programs with this focus.

What does a confidence-building biosimilar campaign look like in practice?

A confidence-building campaign works as one coordinated strategy across prescribers, payers and patients, where each audience’s confidence reinforces the others. Prescriber confidence eases patient conversations, and payer coverage removes barriers for both.

Five components strong campaigns share:

• Pre-launch scientific exchange. Medical affairs and marketing begin clinical conversations through advisory boards, congresses and peer programs before launch.
• Consistent positioning. Every audience hears the same core message about FDA’s standards and the supporting data; inconsistency invites doubt.
• Segmented content. A prescriber site, a payer evidence dossier and patient support resources serve different needs. Our content strategy services help structure them.
• Ongoing real-world evidence. Add registry data, post-marketing results and published practice experience as they become available.
• Field readiness. Sales and medical teams need training on clinical objections, with clear, compliant answers to the most common questions.

All promotional claims must stay consistent with FDA-approved labeling and FDA’s guidance on promotional labeling and advertising for biosimilars.

How can Emulent help with your biosimilar marketing strategy?

Emulent partners with pharmaceutical and healthcare marketing teams on content strategy, medical education programs and digital campaigns that build trust in the biosimilar category over time, reaching prescribers, payers and patients with the right message at the right stage.

A counterpoint: as FDA moves to treat biosimilars more like generics and more competitors enter each molecule, differentiation may shift from clinical messaging toward price, supply reliability and patient support. Plan for both.

Contact Emulent if you’re planning a biosimilar launch or working to improve uptake.